163 related articles for article (PubMed ID: 35794801)
1. Vitamin A supplementation for the prevention of chronic lung disease in premature infants: A cost-utility analysis.
Buendía JA; Guerrero Patiño D; Lindarte EF
Pediatr Pulmonol; 2022 Oct; 57(10):2511-2517. PubMed ID: 35794801
[TBL] [Abstract][Full Text] [Related]
2. Podotimod in pediatric recurrent respiratory tract infections: a cost-utility analysis.
Buendía JA; Guerrero Patiño D; Lindarte EF
BMC Pulm Med; 2022 Jun; 22(1):244. PubMed ID: 35739542
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility of vitamin D supplementation to prevent acute respiratory infections in children.
Buendía JA; Patiño DG
Cost Eff Resour Alloc; 2023 Apr; 21(1):23. PubMed ID: 37024913
[TBL] [Abstract][Full Text] [Related]
4. Cost utility of vitamin D supplementation in adults with mild to moderate asthma.
Antonio Buendía J; Rodriguez-Martinez CE; Sossa-Briceño MP
J Asthma; 2023 May; 60(5):951-959. PubMed ID: 35920247
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D supplementation for children with mild to moderate asthma: an economic evaluation.
Antonio Buendía J; Patiño DG; Lindarte EF
J Asthma; 2023 Sep; 60(9):1668-1676. PubMed ID: 36755388
[TBL] [Abstract][Full Text] [Related]
6. Cost-Utility of Continuous Positive Airway Pressure for Respiratory Distress in Preterm Infants in a Middle-Income Country.
Buendía JA; Hernández-Sarmiento R; Rojas Medina JE
Value Health Reg Issues; 2023 May; 35():1-7. PubMed ID: 36657278
[TBL] [Abstract][Full Text] [Related]
7. OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysis.
Buendía JA; Patiño DG; Lindarte EF
BMC Pulm Med; 2022 Dec; 22(1):465. PubMed ID: 36474205
[TBL] [Abstract][Full Text] [Related]
8. Ambrisentan for in pediatric pulmonary arterial hypertension: A cost-utility analysis.
Buendía JA; Patiño DG; Lindarte EF
Pediatr Pulmonol; 2023 May; 58(5):1562-1568. PubMed ID: 36797849
[TBL] [Abstract][Full Text] [Related]
9. Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.
Sanchez-Luna M; Burgos-Pol R; Oyagüez I; Figueras-Aloy J; Sánchez-Solís M; Martinón-Torres F; Carbonell-Estrany X
BMC Infect Dis; 2017 Oct; 17(1):687. PubMed ID: 29041909
[TBL] [Abstract][Full Text] [Related]
10. Vitamin A supplementation to prevent mortality and short- and long-term morbidity in very low birth weight infants.
Darlow BA; Graham PJ; Rojas-Reyes MX
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD000501. PubMed ID: 27552058
[TBL] [Abstract][Full Text] [Related]
11. Cost-utility analysis of dupilumab add on therapy versus standard therapy in adolescents and adults for severe asthma in Colombia.
Antonio Buendía J; Patiño DG
Expert Rev Pharmacoecon Outcomes Res; 2022 Jun; 22(4):575-580. PubMed ID: 34860616
[TBL] [Abstract][Full Text] [Related]
12. Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates.
Shah SS; Ohlsson A; Halliday H; Shah VS
Cochrane Database Syst Rev; 2003; (1):CD002058. PubMed ID: 12535425
[TBL] [Abstract][Full Text] [Related]
13. Vitamin A supplementation to prevent mortality and short and long-term morbidity in very low birthweight infants.
Darlow BA; Graham PJ
Cochrane Database Syst Rev; 2007 Oct; (4):CD000501. PubMed ID: 17943744
[TBL] [Abstract][Full Text] [Related]
14. Vitamin A supplementation for preventing morbidity and mortality in very low birthweight infants.
Darlow BA; Graham PJ
Cochrane Database Syst Rev; 2000; (2):CD000501. PubMed ID: 10796372
[TBL] [Abstract][Full Text] [Related]
15. Vitamin A supplementation to prevent mortality and short- and long-term morbidity in very low birthweight infants.
Darlow BA; Graham PJ
Cochrane Database Syst Rev; 2011 Oct; (10):CD000501. PubMed ID: 21975731
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .
Lanctôt KL; Masoud ST; Paes BA; Tarride JE; Chiu A; Hui C; Francis PL; Oh PI
Curr Med Res Opin; 2008 Nov; 24(11):3223-37. PubMed ID: 18928643
[TBL] [Abstract][Full Text] [Related]
17. Early administration of inhaled corticosteroids for preventing chronic lung disease in very low birth weight preterm neonates.
Shah VS; Ohlsson A; Halliday HL; Dunn M
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD001969. PubMed ID: 28052185
[TBL] [Abstract][Full Text] [Related]
18. Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates.
Shah V; Ohlsson A; Halliday HL; Dunn MS
Cochrane Database Syst Rev; 2000; (2):CD001969. PubMed ID: 10796275
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of inhaled nitric oxide in preterm infants undergoing mechanical ventilation.
Zupancic JA; Hibbs AM; Palermo L; Truog WE; Cnaan A; Black DM; Ballard PL; Wadlinger SR; Ballard RA;
Pediatrics; 2009 Nov; 124(5):1325-32. PubMed ID: 19841125
[TBL] [Abstract][Full Text] [Related]
20. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
Wang D; Bayliss S; Meads C
Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
